0001209191-18-038845.txt : 20180620 0001209191-18-038845.hdr.sgml : 20180620 20180620175851 ACCESSION NUMBER: 0001209191-18-038845 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180620 FILED AS OF DATE: 20180620 DATE AS OF CHANGE: 20180620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fowler John Franklin CENTRAL INDEX KEY: 0001744263 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38542 FILM NUMBER: 18910339 MAIL ADDRESS: STREET 1: C/O KEZAR LIFE SCIENCES, INC. STREET 2: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kezar Life Sciences, Inc. CENTRAL INDEX KEY: 0001645666 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473366145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-822-5600 MAIL ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-06-20 0 0001645666 Kezar Life Sciences, Inc. KZR 0001744263 Fowler John Franklin C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 CEO Common Stock 292704 D Employee Stock Option (Right to Buy) 0.90 2025-09-09 Common Stock 156421 D Employee Stock Option (Right to Buy) 1.41 2026-09-14 Common Stock 48932 D Employee Stock Option (Right to Buy) 2.37 2027-10-09 Common Stock 177935 D Employee Stock Option (Right to Buy) 2.37 2028-01-06 Common Stock 88967 D Employee Stock Option (Right to Buy) 5.91 2028-04-15 Common Stock 133451 D Twenty-five percent (25%) of the shares subject to the option shall vest on June 11, 2016, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to the Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to the option shall vest on June 11, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to the Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to the option shall vest on July 21, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date. One forty-eighth (1/48th) of the shares shall vest on a monthly basis, on the last day of the month, commencing on the January 1, 2018, subject to the Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to the option shall vest on January 1, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to the Reporting Person continuing to provide service through each such date. /s/ Laura Berezin, Attorney-in-Fact 2018-06-20 EX-24.3_797603 2 poa.txt POA DOCUMENT POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of Laura Berezin of Cooley LLP, and Christopher J. Kirk, Marc Belsky and Michael Wolfe of Kezar Life Sciences, Inc. (the "Company"), signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC"), a Form ID and Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company; (2) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form ID and Forms 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and (3) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion. The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or employed by or a partner at Cooley LLP or another law firm representing the Company, as applicable. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below. Date: June 14, 2018 By: /s/ John F. Fowler John F. Fowler